Scale up and In-vitro Testing of Exosomes for Regenerative Medicine Applications

Stem cell-secreted exosomes are gaining significant attention as a candidate therapeutic platform for 21st century healthcare. This is because a growing body of research into exosomes has revealed that they can drive desirable behavioural changes in target cells, modifying or reversing pathological processes. The potential applications of exosomes are broad and include cell-free regenerative medicine at one end of the spectrum and cancer therapeutic at the other. To fully understand the therapeutic repertoire of exosomes, it is necessary to systematically characterise exosome populations isolated from a range of different cell culture scenarios. Critical for commercial development, it is also necessary to generate exosomes in therapeutically relevant quantities, which requires the creation of a cell culture process that can be scaled up to deliver industrial quantities of exosome product. Using bench-scale bioreactors that mimic industrial bioreactor technologies, this project will draw on expertise across bioprocess engineering for regenerative medicines in order to scale up production of stem cells and their exosomes. It will then use microfluidics and analytics for in vitro testing of exosome potency. This can be achieved using automated, perfused cell culture devices that support in situ monitoring of how exosomes influence the behaviour of 3D microtissues. 3D microtissues will be created using cells and biomaterials to create self-assembled tissues. The microfluidic devices will result in minimal operator error and increased measurement consistency.